A Single-center, Open-label, Single Dose, Randomized, Two-way Cross-over Study to Investigate the Pharmacokinetics, Safety, and Tolerability of RO4917838 in Healthy Chinese Volunteers
Phase of Trial: Phase I
Latest Information Update: 14 Sep 2015
At a glance
- Drugs Bitopertin (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Roche
- 21 May 2012 Actual initiation date (Sep 2011) added as reported by ClinicalTrials.gov.
- 21 May 2012 Actual end date (April 2012) added as reported by ClinicalTrials.gov.
- 21 May 2012 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.